As advanced therapy medicinal products (ATMPs) continue to gain momentum, so does the need for more rigorous and responsive safety testing. Access this insightful resource to explore how next-generation sequencing (NGS) is reshaping viral risk mitigation. Discover why NGS is quickly moving from optional to essential in the ATMP development lifecycle, with an important look at: Detection capabilities that identify both known and unknown viruses without prior sequence knowledge High sensitivity and broad applicability across diverse ATMP platforms, including gene and cell therapiesEvolving regulatory expectationsThe potential to streamline testing workflows, reduce reliance on animal-based methods, and lower long-term costs Tips for future-proofing viral safety strategiesAnd more |
